MNKD241122P2000
- 0.00
- 0.000.00%
MannKind Newsroom
Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7
Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Maintains Target Price $12
IntegriChain Revenue Optimization Experts to Speak at Informa's Pharma/BioTech GTN Summit
MannKind's Growth Momentum and Increased Confidence in Pipeline Elevate Buy Rating
Q3 2024 MannKind Corp Earnings Call
RBC Capital Sticks to Its Hold Rating for MannKind (MNKD)
Express News | MannKind Corp : RBC Raises Target Price to $7 From $5
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript Summary
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
Express News | MannKind Corp -Qtrly Adj Basic EPS $0.06
MannKind Corp. Q3 Profit Increases, Beats Estimates
MannKind | 10-Q: Q3 2024 Earnings Report
MannKind: Orphan Lung Disease Studies Proceeding as Planned >MNKD
MannKind | 8-K: MANNKIND CORPORATION REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Conference Call to Begin Today at 4:30 p.m. (ET)
Earnings Flash (MNKD) MANNKIND Posts Q3 EPS $0.06
MannKind Non-GAAP EPS of $0.06 Beats by $0.03, Revenue of $70.08M Misses by $4.41M
MannKind 3Q EPS 4c >MNKD
MannKind 3Q Rev $70.1M >MNKD
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Hims & Hers Health (HIMS) and MannKind (MNKD)